Brief: Maia Biotechnology Says Lans To Initiate A Phase 3 Pivotal Trial In 2025, Named Thio-104
27/02/2025 23:31
Feb 27 (Reuters) - Maia Biotechnology Inc MAIA.A: MAIA BIOTECHNOLOGY INC: LANS TO INITIATE A PHASE 3 PIVOTAL TRIAL IN 2025, NAMED THIO-104 MAIA BIOTECHNOLOGY EXPECTS TO BEGIN ENROLLING PATIENTS IN THIO-104 IN SECOND HALF OF 2025 IN SELECT COUNTRIES IN ASIA, EUROPE, U.S Source text: [ID:n0001493152-25-008540] Further company coverage: MAIA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale